CTOs on the Move


 
Covers a range of chronic conditions— impacting over 50% of employees Type 2 DiabetesPrediabetesClinical ObesityNAFLD
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.daytwo.com
  • 2121, North California Boulevard
    Walnut Creek, CA USA 94596

Executives

Name Title Contact Details

Similar Companies

HintMD

HintMD is the first consumer platform to combine physician expert support, leading products, and cloud-based technology to deliver a personalized aesthetic experience. Simply complete your profile on HintMD.com, and one of our board-certified aesthetic physicians will invite you for a no-cost consultation. During this first visit, your physician expert will customize a beauty plan to your personal needs, and budget. For one easy monthly membership - receive all the services and products you need - plus earn rewards for staying beautiful. It’s that easy! HintMD keeps you looking great with notifications when its time for your next physician treatment, plus free shipping of skincare when you need it.

Zufall Health Center

Zufall Health Center is a Dover, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nurtur Health, Inc.

Nurtur Health, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Lifestar Ambulance

Lifestar Ambulance is a Centralia, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.